Liquidia Corporation

Good morning and welcome everyone to the Liquidity Corporation's second quarter 2023 financial results and corporate update conference call. My name is Livia and I'll be your conference operator today. Currently all participants are on a listen-only mode. Following the presentation, we will conduct a question and answer session. Instructions will be provided at that time for you to queue up for questions. I would like to remind everyone that this conference call is being recorded. I will now hand the conference call over to Jason Adair, Chief Business Officer.

Thank you, Livia. It's my pleasure to welcome everyone to Liquidia's second quarter 2023 financial results and corporate update call. Joining the call today are Chief Executive Officer, Dr. Roger Jeffs, Chief Financial Officer, Michael Cassetta, General Counsel, Rusty Schundler, and Chief Medical Officer, Dr. Rajiv Sagar. Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause actual results or performance to be materially different from any future results or performance expressed or implied on this call. For additional information, including a detailed discussion of our risk factors, Please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website. I'd now like to turn the call over to Roger for our prepared remarks, after which he'll open the call up for your questions.

Good morning, everyone, and thank you for joining us. In our opening remarks today, we're going to take a very focused approach to address the issue that is most top of mind for our company, our employees, and our shareholders, specifically the path forward as we see it to the successful resolution of the litigation and launch of Utrepia for both PAH and PHILD. I will note, however, that in addition to the significant legal de-risking that Rusty will talk about shortly, we also achieved other major and important milestones in the quarter, most notably the license of L606, a Phase III clinical program for twice-daily liposomal formulation of inhaled troposinol that positions us with the best-in-class portfolio of inhaled troposinol products to best address patient needs, not only today, but also in the future. As mentioned, The bulk of our prepared remarks will focus on the recent legal and regulatory actions related to the ongoing litigation. I've asked Rusty to elaborate on four specific points. First, the favorable affirmation by the Federal Circuit that we do not infringe any valid claims of the 066 patent. Second, our confidence that United's attempt to overturn the PTAT's decision on the 793 patent will fail. Third, positive impact in submitting an amendment to add the PHILD indication to EUTREPIA's label. And lastly, our confidence in why we feel that the recently allowed patent claims to United Therapeutics related to the treatment of PHILD will not be an impediment to EUTREPIA. Rusty?